neowise biotech
- Biotech or pharma, therapeutic R&D
Neowise is a clinical-stage company focusing on developing TCR-T cell therapy against solid tumors. Leveraging its proprietary high-throughput TCR-antigen screening platform, neowise is building the world’s largest Paired Antigen-TCR Library. This library enables the rapid selection of TCRs that recognize antigens present in a patient’s tumor. Positive clinical results have been observed in multiple indications, including colorectal cancer, pancreatic cancer and ovarian cancer. Meanwhile, neowise is also collaborating with MNCs to develop universal CAR-T and TCR bispecifics.